The lung medicine industry has experienced remarkable transformation, driven by escalating respiratory disease prevalence, breakthrough delivery system innovations, and novel therapeutic agent emergence. Respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, pulmonary arterial hypertension (PAH), cystic fibrosis, idiopathic pulmonary fibrosis (IPF), and acute...